HomeQuestion
How do you choose between a PPAR agonist, obeticholic acid, or a fibrate as second-line therapy in PBC with optimized ursodeoxycholic acid when the immediate priority is clinically significant pruritus but you also want to optimize long-term biochemical risk reduction?
1 Answers
Mednet Member
Hepatology · UChicago Medicine
I would prioritize the disease-modifying treatments first for their ability to modify the course of the disease, while at the same time, they may also alleviate pruritus. Elafibranor, for example, has had some antipruritic effects.